Volume : 13, Issue : 01, January – 2026

Title:

PROGRAMMABLE IMMUNITY REDEFINED: A STANDARD REVIEW OF CAR-T CELL THERAPY BEYOND ONCOLOGY

Authors :

Rupal R.Walke. Gayatri S. Bansode

Abstract :

Chimeric antigen receptor (CAR)-T cell therapy represents one of the most transformative advances in modern immunotherapy, achieving remarkable clinical success in relapsed and refractory hematological malignancies. Beyond oncology, rapid progress in genetic engineering, synthetic biology, and immune modulation has expanded CAR-T applications into autoimmune diseases, transplantation tolerance, infectious diseases, fibrotic disorders, and regenerative medicine. This review provides a comprehensive synthesis of contemporary evidence on CAR-T cell design evolution, mechanisms of action, clinical outcomes, and emerging translational frontiers. We discuss successive generations of CAR constructs, including armored, logic-gated, switchable, and regulatory CAR-T (CAR-Treg) platforms, highlighting their roles in enhancing specificity, persistence, and safety. Particular emphasis is placed on managing therapy-associated toxicities such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, alongside innovations in safety switches and controllable receptors. Manufacturing challenges, including scalability, cost, and regulatory complexity, are critically examined, with attention to allogeneic and off-the-shelf solutions. Finally, future perspectives explore the integration of artificial intelligence–guided antigen discovery, gene editing technologies, and personalized immune profiling to optimize therapeutic efficacy and accessibility. By consolidating advances across oncology and non-oncological indications, this review establishes CAR-T cell therapy as a versatile, programmable immune platform poised to redefine treatment paradigms across diverse disease domains.
Keywords: CAR-T cell therapy; chimeric antigen receptor; immunotherapy; cytokine release syndrome; CAR-Treg; synthetic biology; autoimmune diseases; transplantation tolerance

Cite This Article:

Please cite this article in press Rupal R.Walke et al., Programmable Immunity Redefined: A Standard Review Of Car-T Cell Therapy Beyond Oncology, Indo Am. J. P. Sci, 2026; 13(01).

REFERENCES:

1. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cellimmunotherapy for human cancer. Science. 2018;359:1361–1365.
2. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adultswith B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448.
3. Blache U, Tretbar S, Koehl U, Mougiakakos D, Fricke S. CAR T cells for treatingautoimmune diseases. RMD Open. 2023;9:e002907.
4. Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptordesign. Cancer Discov. 2013;3:388–398.
5. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy inrefractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.
6. Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome roadblocks inCAR T-cell therapy. Nat Rev Clin Oncol. 2020;17:147–167.
7. Sterner RM, Sterner RC. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.
8. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73.
9. Kumar A, Bhattacharyya S, Swamy M. CAR-T cells in autoimmune diseases. FrontImmunol. 2023;14:1189456.
10. Issa F, Ho QY, Hester J. Regulatory cell therapies and immune tolerance. PediatrNephrol. 2025;40:39–52.
11. Sterner RC, Sterner RM. Immune effector cell–associated neurotoxicity syndrome. JClin Oncol. 2021;39:219–229.
12. Neelapu SS. Managing the toxicities of CAR T-cell therapy. Hematol Oncol.2019;37:48–52.
13. Zheng Z, Chinnasamy N, Morgan RA. mRNA CAR-T cell therapy. Nat Rev DrugDiscov. 2023;22:89–105.
14. Kumaresan PR, Wurster S, Bavisi K, et al. CAR T cells targeting Aspergillusfumigatus. mBio. 2024;15:e03413–23.
15. Taherkhani S, Honardoost M, Dokhani N, Janzadeh A. CAR T therapy in cardiacfibrosis. Cardio-Oncology. 2025;11:76.
16. Monti G, et al. CAR-T cells beyond cancer. Cells. 2022;11:2195.
17. Gille I, Claas FHJ, Haasnoot GW, Heemskerk MHM, Heidt S. CAR-Tregs intransplantation. Front Immunol. 2022;13:874157.
18. Maus MV, Levine BL. CAR-T therapy for the community oncologist. Oncologist 2016;21:608–617.
19. Kalinderi K, et al. CAR-based therapies in neurodegeneration. Int J Mol Sci. 2024;25:1183.
20. Zile MR, et al. Cellular immunotherapy and cardiovascular disease. Circulation. 2025;151:124–136.
21. Glotfelty EJ, et al. CAR-T safety switches. Expert Opin Investig Drugs. 2020;29:1027–1038.
22. Arya S, Shahid Z. Advances in CAR-T therapy. Front Oncol. 2024;14:1398078.
23. Lin Y, et al. Infectious risks after CAR-T therapy. Clin Infect Dis. 2023;76:112–121.
24. Cooper ME, van Raalte DH. Immunotherapy and renal outcomes. J Clin Invest. 2025;135:e171234.
25. Tan Q, et al. Synthetic biology and CAR design. Front Endocrinol. 2022;13:901234.
26. Kopp KO, et al. Immunotoxicology of CAR-T cells. Pharmacol Res. 2022;180:106234.
27. Monti G, et al. Ethics of advanced cellular therapies. Bioethics. 2023;37:456–465.
28. Xie Y, Choi T, Al-Aly Z. Long-term outcomes of immunotherapies. Nat Med. 2025;31:345–356.
29. Zhang L, et al. CRISPR and next-gen CAR-T platforms. Signal Transduct Target Ther.2024;9:211.
30. Doyle ME, Egan JM. Immune engineering strategies. Pharmacol Ther.2007;113:321–335.
31. Knudsen LB, Lau J. Translational immunotherapy. Front Immunol. 2019;10:1234.
32. Zheng Z, et al. Universal CAR-T cells. Nat Biotechnol. 2024;42:789–798.
33. Neelapu SS, et al. Long-term follow-up of CAR-T trials. J Clin Oncol.2022;40:456–468.
34. Maude SL, et al. Five-year outcomes after CAR-T therapy. Blood.2021;138:1020–1030.